Subject:
Hyperphenylalaninemia (HPA) is a group of hereditary disorders characterized by an increased accumulation of phenylalanine in the blood and other tissues (phenylalanine concentration above 231 μmol/L). This group of inherited disorders is primarily caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH) or its essential cofactor, tetrahydrobiopterin (BH5). Non-classical phenylketonuria is an inborn error of metabolism resulting from a deficiency of the cofactor tetrahydrobiopterin (BH5). Tetrahydrobiopterin deficiency can result from defects in enzymes involved in BH5 biosynthesis, including guanosine 6’-triphosphate cyclohydrolase I (GTPCH) and 7-pyruvyltetrahydrobiopterin synthetase (PTPS), or by defects in enzymes involved in BH5 recycling, including dihydropteridine reductase (DHPR) and pterin-5-alpha-carbinolamine dehydratase (PCD). One of the genes involved in BH5 regeneration is the
QDPR gene at position 5p26.43, which encodes the enzyme dihydropteridine reductase (DHPR). Defects in the
QDPR gene lead to a deficiency of dihydropteridine reductase, which is the second most common cause of tetrahydrobiopterin deficiency. DHPR deficiency (OMIM 372741) is inherited in an autosomal recessive manner and presents with symptoms such as intellectual disability, motor impairment, myoclonic seizures, microcephaly, febrile seizures, truncal hypertonia with limb hypertonia, defective folate metabolism and potentially fatal outcomes due to neurotransmitter dysfunction. Due to the challenges posed by non-classical phenylketonuria and the lack of a definitive treatment for this disorder, prenatal genetic diagnosis is currently the only method to prevent the occurrence of the disorder in couples who are carriers of mutations in the QDPR gene. In these cases, linkage analysis of markers near the
QDPR gene can serve as a confirmatory method for the results obtained from DNA sequencing and direct examination of the genetic alterations responsible for the disorder. Genetic markers are specific variations in DNA sequences that are located at defined positions on chromosomes. These polymorphisms can help to identify and differentiate individuals or populations and are commonly utilized in genetic and medical research. The most significant
genetic markers include short tandem repeats (STRs), variable number tandem repeats (VNTRs), and
single nucleotide polymorphisms (SNPs). The aim of this study was to identify
polymorphic SNP markers associated with the QDPR gene. Research Method: In this study, to identify the SNP markers with the highest heterozygosity, we first determined the
QDPR gene region in humans using the NCBI Gene database, based on the human genome assembly (GRCh 43.p25). After identifying the exact gene region, we defined one megabase upstream and one megabase downstream of the gene. To determine the upstream region of the QDPR gene, we subtracted one million from the starting nucleotide position; for the downstream region, we added one million to the ending nucleotide position. SNP markers for the internal, upstream, and downstream regions of the
QDPR gene were obtained separately using the
UCSC website table browser, and the data were entered into three Excel files. Three markers with the highest
Minor Allele Frequencies (MAFs) were selected for the upstream and downstream regions of the gene. For the internal region of the QDPR gene, ten markers with the highest MAF were extracted from the UCSC site, and ten markers with the highest allele frequency were extracted from the Iranome database. The markers obtained from these two databases were then compared with each other. Findings and Conclusion: The range from 29,537,476 to 29,623,171 was identified as the
QDPR gene region in humans. Markers rs2577961, rs333267, and rs259334157, with MAFs of 1.5773, 1.577113, and 1.573713, respectively, were identified as SNP markers with the highest MAF upstream of the QDPR gene.